story of the week
Fasting Glucose and BMI Predict Activity in Breast Cancer Patients Treated With Everolimus-Exemestane
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Scientific Reports
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fasting Glucose and Body Mass Index as Predictors of Activity in Breast Cancer Patients Treated With Everolimus-Exemestane: The EverExt Study
Sci Rep 2017 Sep 06;7(1)10597, L Pizzuti, P Marchetti, C Natoli, T Gamucci, D Santini, AF Scinto, L Iezzi, L Mentuccia, L D'Onofrio, A Botticelli, L Moscetti, F Sperati, C Botti, F Ferranti, S Buglioni, G Sanguineti, SD Filippo, LD Lauro, D Sergi, T Catenaro, S Tomao, A Giordano, M Maugeri-Saccà, M Barba, P ViciFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.